E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10039626 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy of aripiprazole intramuscular (IM) depot administration against oral aripiprazole, measured in terms of time to psychotic symptom exacerbation or impending relapse, in schizophrenic patients who have maintained stability with oral aripiprazole for at least 8 weeks. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the safety and tolerability of aripiprazole IM depot administration as maintenance therapy in schizophrenic patients. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Screening: 1)Subjects who are able to provide written informed consent and/or consent obtained from a legally acceptable representative (as required by IRB/IEC), prior to the initiation of any protocol-required procedures. 2)Male and female subjects 18 to 60 years of age, inclusive, at time of informed consent. 3)Subjects with a current diagnosis of schizophrenia as defined by DSM-IV-TR criteria and a history of the illness for at least three years prior to screening. 4)Subjects who, in the investigators judgment, require chronic treatment with antipsychotic medication(s). 5) Subjects who showed previous response to antipsychotic treatment (other than clozapine) in the past year, according to the investigators opinion. 6)Subjects who are currently being treated with oral or depot antipsychotics other than clozapine (a recent lapse in antipsychotic treatment will be considered as currently being treated for the purpose of determining eligibility for this trial) and who, in the investigators judgment, would benefit from treatment with aripiprazole IM depot. 7)Subjects with a history of relapse and/or exacerbation of symptoms when they are not receiving antipsychotic treatment. 8)Inpatient or outpatient status prior to entry into Phase 2 (oral stabilization) 9)Subjects able to understand the nature of the study and follow protocol requirements, including the prescribed dosage regimens, tablet ingestion, IM depot injection, discontinuation of prohibited concomitant medications, who can read and understand the written word in order to complete patient-reported outcomes measures, and who can be reliably rated on assessment scales. Prior to Entry into Phase 1: 10) Adequate washout of prohibited concomitant medications, including 3 days prior to entry into Phase 1 for mood stabilizers and antidepressants (14 days for fluoxetine or Symbyax). 11)Subject is receiving no more than one benzodiazepine beyond screening*. 12) Inpatient or outpatient status 13) Subject is receiving antipsychotic(s) other than aripiprazole or clozapine and must be cross-titrated to aripiprazole monotherapy over 4 to 6 weeks using an initial dose of 5 mg to achieve a recommended target aripiprazole monotherapy starting dose in Phase 2 of 10 or 15 mg*. Prior to Entry into Phase 2: 14) Adequate washout of prohibited concomitant medications, including 14 days prior to entry into Phase 2 for mood stabilizers and antidepressants (42 days for fluoxetine or Symbyax) and one cycle plus 14 days prior to entry into Phase 2 for approved long-acting antipsychotics (eg, 2-week cycle plus an additional 14 days for risperidone long-acting injection) or 60 days for investigational long-acting antipsychotics. 15) Subject is receiving oral aripiprazole as monotherapy for treatment of schizophrenia at a starting dose of 10 or 15 mg daily*. 16) Inpatient or outpatient status. Prior to Entry into Phase 3: 17) Subject is receiving oral aripiprazole as monotherapy for treatment of schizophrenia at a dose ranging from 10 to 30 mg daily. 18) Outpatient status 19) Subjects condition is stable as evidenced by meeting ALL of the following criteria for 8 consecutive weeks (4 consecutive bi-weekly visits), including the last visit prior to entering Phase 3: a) Outpatient status b) PANSS Total Score ≤ 80 c) Lack of specific psychotic symptoms as measured by a score of ≤ 4 on the following PANSS items: Conceptual disorganization Suspiciousness Hallucinatory behavior Unusual thought content d) CGI-S ≤ 4 (moderately ill) e) CGI-SS ≤ 2 (mildly suicidal) on Part 1 and ≤ 5 (minimally worsened) on Part 2* 20) Stability criteria are met on or before Week 28 of Phase 2. * See Protocol for explanatory details |
|
E.4 | Principal exclusion criteria |
1) Sexually active males and females of childbearing potential who are not practicing double-barrier birth control or who will not remain abstinent during the study and for 180 days (150 for female) following the last dose of study medication.If employing birth control, two precautions to be used*. 2) Females who are breast-feeding and/or who have a positive serum pregnancy test result prior to receiving study drug. 3) Subjects with a current DSM-IV-TR diagnosis other than schizophrenia, including schizoaffective disorder, major depressive disorder, bipolar disorder, delirium, dementia, amnestic or other cognitive disorders.Also, subjects with borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial personality disorder. 4) Subjects experiencing acute depressive symptoms within the past 30 days, according to the investigators opinion, that requires treatment with an antidepressant. 5) Subjects with schizophrenia that are considered resistant/refractory to antipsychotic treatment by history. 6)Subjects with a history of failure to clozapine treatment or response to clozapine treatment only. 7) Subjects with a significant risk of violent behavior or a significant risk of committing suicide based on history or investigators judgment. 8) Subjects who currently meet DSM-IV-TR criteria for substance dependence; including alcohol and benzodiazepines, but excluding caffeine and nicotine. 9) Subjects with hypothyroidism or hyperthyroidism (unless condition has been stabilized with medications for at least the past 90 days)*. 10) Subjects who have a history or evidence of a medical condition that would expose them to an undue risk of a significant adverse event or interfere with assessments of safety or efficacy during the course of the trial*. 11)Subjects with epilepsy or a history of seizures, except for a single childhood febrile seizure, post traumatic, alcohol withdrawal, etc. 12) Subjects with two positive drug screens for cocaine prior to Phase 2*. 13) Abnormal laboratory test, vital sign, and ECG results*. 14) Subjects who are known to be allergic, intolerant, or unresponsive to prior treatment with aripiprazole or other quinolinones. 15)Subjects with a history of hypersensitivity to antipsychotic agents. 16) Subjects who are known to be allergic, intolerant, hypersensitive, or refractory to antipsychotic agents. 17) Subjects with a history of neuroleptic malignant syndrome or clinically significant tardive dyskinesia at screening. 18) Subjects likely to require prohibited concomitant therapy during the trial. 19)Subjects receiving CYP2D6 or CYP3A4 inhibitors or CYP3A4 inducers at screening or anticipated use of such agents during the trial*. 20)Subjects who received any investigational agent in a clinical trial within 30 days prior to screening or who were randomized into a clinical trial with aripiprazole IM depot at any time. 21) Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (eg, infectious disease) illness must not be enrolled into this trial. 22.Subjects who have been hospitalized, including hospitalization for psychosocial reasons, for more than 30 days total in the last 90 days prior to entry into Phase 1 for subjects entering Phase 1, or prior to Phase 2 for subjects entering Phase 2 directly after screening. 23)Electroconvulsive therapy within 180 days prior to entry into Phase 2. 24) Subjects who have more than one excursion from stability criteria after achieving a response to oral aripiprazole at a point in the trial where they would not be able to maintain stability for a minimum of 8 weeks without exceeding 28 weeks total in Phase 2. 25) Subjects who have not achieved stability criteria on oral aripiprazole for 8 consecutive weeks (4 consecutive bi-weekly visits) by W28 of Phase 2 or who have consecutive excursions at W20 and W22. * See Protocol for explanatory details |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy endpoint of this study is the time from randomization to exacerbation of psychotic symptoms/impending relapse in Phase 3, defined as meeting any or all of the following four criteria: 1) CGI-Improvement of ≥ 5 (minimally worse) AND an increase on any of the following individual PANSS items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content) to a score > 4 with an absolute increase of � 2 on that specific item since randomization OR an increase on any of the following individual PANSS items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content) to a score > 4 and an absolute increase of � 4 on the combined four PANSS items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content) since randomization. OR 2) Hospitalization due to worsening of psychotic symptoms (including partial hospitalization programs), but excluding hospitalization for psychosocial reasons OR 3) CGI-SS of 4 (severely suicidal) or 5 (attempted suicide) on Part 1 and/or 6 (much worse) or 7 (very much worse) on Part 2 OR 4) Violent behavior resulting in clinically significant self-injury, injury to another person, or property damage. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.3.1 | Comparator description |
- same IMP used at different dosage |
|
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 60 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 0 |